Lipitor 20 mg is an oral tablet containing atorvastatin, a statin that reduces cholesterol production in the liver. The reviewed US information describes treatment of specified lipid disorders and reduction of cardiovascular events in selected people at risk. It is used alongside appropriate lifestyle measures; the goal depends on the patient\u2019s cardiovascular history and lipid results.<\/p>\n
This page concerns the Lipitor tablet rather than another statin or a combination product. A 20 mg strength does not identify the right treatment intensity for every person. Cholesterol usually cannot be judged from how someone feels, so follow-up blood tests and clinical review remain important even when there are no symptoms.<\/p>\n
Diarrhoea, nausea, joint discomfort and muscle symptoms can occur. Report unexplained muscle pain, tenderness or weakness promptly, especially with fever, unusual tiredness or dark urine: rare muscle breakdown can affect the kidneys. Persistent muscle weakness needs assessment even if another clinician has already advised stopping the medicine.<\/p>\n
Yellowing of the eyes or skin, significant upper abdominal pain, dark urine or unusual fatigue can indicate liver injury. The US label advises liver testing before treatment and when clinically indicated. Blood glucose can increase in some people. These possibilities require assessment of the individual benefit and risk, rather than assuming that every symptom is caused by the statin.<\/p>\n
Certain antivirals, macrolide antibiotics and azole antifungals can increase atorvastatin exposure and muscle risk. Ciclosporin, some other cholesterol-lowering medicines and colchicine also need specific checks. Large quantities of grapefruit juice can increase exposure; the relevant amount and management should be discussed for the exact product and regimen. Do not apply another statin\u2019s interaction instructions automatically.<\/p>\n
Pregnancy wording here follows the current US approach. FDA removed the blanket pregnancy contraindication for statins in 2021, while advising that most pregnant patients should discontinue them under clinical supervision. A small group with very high cardiovascular risk may need a different decision. This does not establish routine pregnancy safety. The US Lipitor information does not recommend breastfeeding during treatment. Local product information may differ, so pregnancy, pregnancy planning or breastfeeding should trigger a prompt discussion with the prescriber.<\/p>\n
Source check: